68Ga-PSMA PET is a rapidly evolving imaging modality for whole-body staging of prostate cancer. We report a case of a 70-year-old man with mildly elevated prostate-specific antigen (8.1 μg/L) and clinical suspicion of prostate cancer (osteoblastic metastases on radionuclide bone scan) who was referred for 68Ga-PSMA PET/CT for primary staging. Multiple 68Ga-PSMA–avid skeletal foci, mostly associated with lytic changes on low-dose CT, as well as hepatic foci of avid 68Ga-PSMA uptake, were identified. No abnormal focus of avid 68Ga-PSMA uptake was identified in the prostate. On histopathological examination, the liver lesion proved to be combined hepatocellular cholangiocarcinoma.
From the *Department of Nuclear Medicine and PET, John Hunter and Calvary Mater Hospitals, Newcastle; †Faculty of Health, University of Newcastle; and ‡Department of Nuclear Medicine and PET, John Hunter and Calvary Mater Hospitals, Newcastle, New South Wales, Australia.
Received for publication May 22, 2017; revision accepted June 17, 2017.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Ramin Alipour, MD, FRACP, FAANMS, Department of Nuclear Medicine and PET, John Hunter Hospital, Locked Bag No 1, HRMC, Newcastle, NSW 2310, Australia. E-mail: Ramin.Alipour@hnehealth.nsw.gov.au.